Given its influence on cytokine networks, a targeted therapeutic could be designed to either enhance or inhibit specific haptoglobin interactions, offering new treatment strategies for conditions such as sepsis, chronic inflammatory diseases, and even cancer (Telen et al., 2019). The gene discussed is HP; the disease is cancer.